MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04165ntm a2200361 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
12102116 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20230810142138.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150118s2021 ua a f bm 000 0 eng | |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-NcFUE |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract/overprinted title or subtitle |
ara |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.19 |
| Item number |
M.Z.A |
| Edition number |
22 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mazayen, Zaed Mazen |
| Relator term |
author |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Application of Nanosizing Technique for Enhancement of Solubility of a Certain Drug / |
| Statement of responsibility, etc |
Zaed Mazen Mazayen, B.SC of Pharmaceutical Sciences and Pharmaceutical Industries 2016, Faculty of Pharmacy, Future University in Egypt In partial fulfillment of the requirements for the degree of Master in Pharmaceutical Sciences Pharmaceutics and Pharmaceutical Technology Under the supervision of Prof. Dr. Ehab Rasmy Bendas Professor of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University, Prof. Dr. Emad Bashir Basalious Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University Dr. Rasha Elbatanony Lecturer of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt. |
| 246 35 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
تطبيق تقنية تصغير الحجم الى النانومتري لتعزيز الذوبان لدواء معين |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2021 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
123 pages, 5 pages : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
24 cm. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 500 ## - GENERAL NOTE |
|---|
| General note |
supervision of Prof. Dr. Omaima A. Sammour, (Professor of Pharmaceutics and Industrial Pharmacy-Faculty of Pharmacy- Ain Shams University), Prof. Dr. Mona Ibrahim Abdeltawab Elassal, (Professor of Pharmaceutics and Industrial Pharmacy- Faculty of Pharmacy- Future university), Dr. Mona Mohamed Ahmed Abdel-Mottaleb, (Associate professor of Pharmaceutics and Industrial Pharmacy-Faculty of Pharmacy- Ain Shams University). |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.)-Ain Shams university, Faculty of pharmacy, Department of Pharmaceutics, 2021. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references. |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc |
Renal allograft survival requires multiple immunosuppressive drugs. This strategy<br/>may lead to gastric complications that necessitate gastro-protective medications,<br/>notably, proton pump inhibitors (PPI). This study aimed to compare the influence<br/>of pantoprazole and esomeprazole on serum cyclosporine trough levels (C0) in<br/>renal transplant recipients (RTR). A prospective, parallel, open-label trial was<br/>conducted on 47 adult RTR receiving cyclosporine doses adjusted to attain trough<br/>concentrations of 100 to 150 μg/L, mycophenolate mofetil (MMF) 750 mg<br/>q12 hour and prednisolone at 5 mg daily at Nasser Institute, Cairo, Egypt from<br/>January to September 2016. Patients were randomized into the esomeprazole<br/>group (25) or pantoprazole group (22) receiving the same dose (40 mg once daily).<br/>The study outcomes included clinical signs of rejection and renal function<br/>decline, assessed by elevations in serum creatinine, caused by cyclosporine level<br/>variations in either of the two study groups. Renal function, C0 and CBC measurements were measured at baseline and monthly for 6 months. The mean C0<br/>values were higher in the pantoprazole group than in the esomeprazole group in<br/>the sixth month only (P = .007). Serum creatinine level was lower in the sixth<br/>month than at baseline in the esomeprazole group (P = .004). There were no<br/>signs of rejection biochemical or clinical in any of the study groups. In conclusion,<br/>PPIs should be used with caution and doses should be titrated to reach the C0 targets in RTR, which is of more importance in pantoprazole than esomeprazole to<br/>avoid C0 level elevation or decline affecting the allograft function |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
Text in English, abstracts in English and Arabic. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmaceutical industry |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmaceutical technology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacology |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Prof. Dr. Bendas, Ehab Rasmy. |
| Relator term |
supervisor |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Prof. Dr. Basalious, Emad Bashir. |
| Relator term |
supervisor |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dr. Elbatanony, Rasha. |
| Relator term |
supervisor |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
DSpace electronic resources |
| Uniform Resource Identifier |
http://repository.fue.edu.eg/xmlui/handle/123456789/5779 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Item type |
Thesis |